The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | The latest trends in the management of oncogene-driven resectable NSCLC
Samuel Rosner, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses current trends in the management of oncogene-driven resectable NSCLC, one significant trend being the use of osimertinib in patients with resected non-small cell lung cancer (NSCLC) harboring an EGFR mutation. Studies have shown improved progression-free survival (PFS) and are likely to demonstrate an overall-survival (OS) benefit. The role of targeted therapies, such as TKIs, in the neoadjuvant setting is being explored, and initial data on the use of osimertinib in this context has been presented. Larger studies are underway to evaluate the effectiveness of targeted therapies in the neoadjuvant setting, and to investigate their potential benefits for other oncogene drivers. The field is currently active with numerous trials, making it an exciting time for advancements in this area. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
